Ask a Patient® Health News: Drugs & Treatments

Home
Notes
Drug Safety Updates
Special Features
Archive
About
December 2024 Drug Safety Updates: Antidepressant and seizure drug recalls; Ocaliva and liver failure; new acne inversa med's label change…
Drug Recalls: Duloxetine and Clonazepam
 • 
Katie Rowley
Skin Reactions and NSAIDs
Safety Labeling Changes for Prescription NSAIDs Warn of Rare but Severe Skin Reactions
 • 
Katie Rowley
November 2024 Drug Safety Updates Part 4: Cancer Drugs: Ayvakit, Keytruda, Oxaliplatin, more
Ayvakit (avapritinib) tablets
 • 
Katie Rowley
Pulmonary Aspiration Warning for GLP-1 (Glucagon-like peptide-1) Diabetes and Weight Loss Meds
GLP-1 medications help patients lose weight by delaying the movement of food from the stomach into the small intestine, suppressing appetite.

November 2024

November 2024 Drug Safety Updates Part 3: Brilinta's interaction with rosuvastatin; Caduet; 3 HIV drugs; ILARIS for autoinflammatory…
Consumer-friendly summaries of new safety information added to Food and Drug Administration (FDA) drug labels
 • 
Katie Rowley
New Brain-Administered Gene Therapy; New drugs for: UTIs, Hemophilia, Stomach Cancer, Breast Cancer
Gene Therapy Stimulates Brain’s Dopamine Production
Recommended Articles and Podcasts on Drugs & Treatments: November 2024
Herbal medicine, independent pharmacy dilemmas, FDA and AI-powered treatments, manufacturing quality, HRT, TV drug advertising changes, insulin pens…
November 2024 Drug Safety Update Part 2: Meds for Prostate Cancer; Leukemia; Hereditary Angioedema; Acute Radiation Syndrome; Heparin Meds
Consumer-friendly summaries of new safety information added to Food and Drug Administration (FDA) drug labels
 • 
Katie Rowley
Phenylephrine-containing OTC oral decongestants on the FDA chopping block; No mention of Rx versions
On November 7, 2024, the FDA announced its proposal to remove oral phenylephrine as an active ingredient in over-the-counter (OTC) medications.
 • 
Katie Rowley
November 2024 Drug Safety Update Part 1: Botox Cosmetic and Dry Eye, Cardio Effects; Antifungals; Briumvi for MS; Biosimilars for Prolia and…
Consumer-friendly summaries of new safety information added to Food and Drug Administration (FDA) drug labels
 • 
Katie Rowley
1

October 2024

October 2024 Drug Safety Update Part 2: Skin Conditions, Eye disease, Leukemia, Lung, Malaria, Overactive Bladder, Type 2, and Tuberculosis…
Consumer-friendly summaries of new safety information added to FDA drug labels
 • 
Katie Rowley
October 8, 2024: Promising schizophrenia drug approved; tirzepatide (Mounjaro and Zepbound) no longer in shortage; real-world performance of…
New Drug Approvals: Cobenfy for Schizophrenia
© 2024 AskaPatient.com
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture